secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001867096-22-000033
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris closes $150M Hayfin debt facility, reports FY2021 product revenue $79M (+56%) and guides FY2022 $105M-$120M
--------------------------------------------------------------------------------

- Xeris drew $100M from new $150M Hayfin term loan (9%+SOFR, warrants at $2.28, 5-yr maturity); repaid $43.5M Oxford/SVB debt.
- FY2021 net product revenue $79M (pro forma), up 56% YoY; net loss $122.7M ($1.55/share) vs $91.1M ($2.14/share) in 2020.
- FY2022 revenue guidance $105M-$120M; year-end cash $90M-$110M; cash flow breakeven targeted by end of 2023.
- Gvoke prescriptions up 85% in Q4, retail share ~17%; Keveyis at high end of $38-40M guidance; Recorlev launched Feb 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000033/0001867096-22-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000033/xers-20220308.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer